Stockreport

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Aktis Oncology, Inc. - Common stock  (AKTS) 
NASDAQ:AMEX Investor Relations: ir.akoustis.com
PDF U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or [Read more]